Tumor-specific immunoglobulin heavy chain variable region third complementarity-determining region

The **tumor-specific VH CDR3 region of immunoglobulin heavy chain** refers to the hypervariable third complementarity-determining region in the variable domain of the immunoglobulin heavy chain (VH CDR3). This region is formed by the recombination of V, D, and J gene segments during B cell development and is the most variable part of the antibody, conferring antigen-binding specificity[2][4][7]. In B-cell malignancies, the clonal nature of the cancer means a single, unique VH CDR3 sequence serves as a molecular signature for the malignant clone. This sequence can be used as a highly specific biomarker for disease detection, minimal residual disease monitoring, and, in some personalized approaches, as a highly specific therapeutic target. However, because every B-cell clone has a unique VH CDR3, this is not a universal target but a clonal, patient- or tumor-specific marker rather than a traditional, broadly druggable molecule[4][5]. This entry is not a canonical drug target but instead a region/sequence whose tumor-specific variant can function as a unique, clonotype-level biomarker and (in experimental approaches) a custom therapeutic target, rather than a conventional receptor or protein family[4][5].

Other names

Immunoglobulin heavy chain CDR3 (HCDR3)Ig VH CDR3Heavy chain third complementarity-determining regionTumor-specific HCDR3

Targeting of unique clonal sequences on malignant B cells by personalized or highly specific therapies (e.g., anti-idiotype antibodies)